Comparison of two types of standard Three drug regimen treatments in dyspepsia due to H. pylori infection.
Not Applicable
- Conditions
- Health Condition 1: K269- Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforationHealth Condition 2: K30- Functional dyspepsiaHealth Condition 3: K259- Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforationHealth Condition 4: K299- Gastroduodenitis, unspecifiedHealth Condition 5: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation
- Registration Number
- CTRI/2020/03/024057
- Lead Sponsor
- DR Rajendra Prasad Government Medical College Kangra at Tanda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Dyspepsia patients (ulcer or non-ulcer) with H. pylori positivity on gastric biopsy.
Exclusion Criteria
1) Patients not willing to give written informed consent.
2) Pregnant females.
3) Lactating females.
4) Active alcohol users.
5) Patients allergic or with known contraindications to any of study drugs.
6) Patients who have already taken either of the above mentioned H. pylori eradication
regimens.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication of Helicobacter pylori as indicated by stool antigenTimepoint: 1.5 months after initiation of treatment.
- Secondary Outcome Measures
Name Time Method To evaluate the safety profile of two triple drug regimenTimepoint: From initiation of treatment to 1.5 months after initiation of treatment.